Eosinophilic lung disease

Clinical Pulmonary Medicine

Volumn 17, Issue 2, 2010, Pages 66-74

  Li, Howard ^a   Groshong, Steven D ^a,b   Lynch, David ^a,b   Brown, Kevin K ^a,b   Frankel, Stephen K ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Acute eosinophilic pneumonia; Allergic bronchopulmonary mycosis; Chronic eosinophilic pneumonia; Churg strauss syndrome; Druginduced lung disease; Eosinophil; Eosinophilic lung disease; Hypereosinophilic syndrome; Interstitial lung disease

Indexed keywords

CORTICOSTEROID; PREDNISONE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; BRONCHOSCOPY; CHURG STRAUSS SYNDROME; CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; EOSINOPHIL COUNT; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LOEFFLER PNEUMONIA; LUNG BIOPSY; LUNG GAS EXCHANGE; LUNG LAVAGE; PARASITOSIS; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

EID: 77952365467     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3181d2a1d6     Document Type: Review

References (87)

1. Chang HW, Leong KH, Koh DR, et al. Clonal origin of eosinophils in the hypereosinophilic syndrome detected by PCR analysis of DNA polymorphisms of the X linked human androgen receptor gene. Int J Hematol. 1996; 64.
2. Chang HW, Leong KH, Koh DR, et al. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999; 93: 1651-1657.
3. Johkoh T, Muller NL, Akira M, et al. Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients. Radiology. 2000; 216: 773-780.
4. Kwong YL, Chan LC. Involvement of eosinophils in acute myeloid leukemia with monosomy 7 demonstrated by fluorescence in situ hybridization. Br J Hematol. 1994; 88: 389-391.
5. Luppi M, Marasca R, Morselli M, et al. Clonal nature of hypereosinophilic syndrome. Blood. 1994; 84: 349-350.
6. Lams BE, Sousa AR, Rees PJ, et al. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 158: 1518-1523.
7. Dippolito R, Foresi A, Chetta A, et al. Eosinophils in induced sputum from asymptomatic smokers with normal lung function. Respir Med. 2001; 95: 969-974.
8. Travis WD. Pathology of pulmonary vasculitis. Semin Respir Crit Care Med. 2004; 25: 475-482.
9. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009; 135: 805-826.
10. Mitchell TA, Hamilos DL, Lynch DA, et al. Distribution and severity of bronchiectasis in allergic bronchopulmonary aspergillosis (ABPA). J Asthma. 2000; 37: 65-72.
11. Ward S, Heyneman L, Lee MJ, et al. Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients. Am J Roentgenol. 1999; 173: 937-942.
12. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest. 2007; 132: 1183-1190.
13. Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977; 86: 405-414.
14. Patterson R, Greenberger PA, Halwig JM, et al. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med. 1986; 146: 916-918.
15. Agarwal R, Gupta D, Aggarwal AN, et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest. 2006; 130: 442-448.
16. Imbeault B, Cormier Y. Usefulness of inhaled high-dose corticosteroids in allergic bronchopulmonary aspergillosis. Chest. 1993; 103: 1614-1617.
17. Balter MS, Rebuck AS. Treatment of allergic bronchopulmonary aspergillosis with inhaled corticosteroids. Respir Med. 1992; 86: 441-442.
18. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003; 111: 952-957.
19. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000; 342: 756-762.
20. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol. 2008; 43: 1249-1251.
21. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax. 2007; 62: 276-277.
22. Ong RK, Doyle RL. Tropical pulmonary eosinophilia. Chest. 1998; 113: 1673-1679.
23. Solomon J, Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med. 2006; 27: 192-197.
24. Frankel SK. Drug-Induced Lung Disease. In: Hanley M, Welsh C, eds. Current Diagnosis and Treatment in Pulmonary Medicine. New York, NY: Lange Medical Bools/McGraw-Hill; 2003: 337-347.
25. Salerno SM, Strong JS, Roth BJ, et al. Eosinophilic pneumonia and respiratory failure associated with a trazodone overdose. Am J Respir Crit Care Med. 1995; 152: 2170-2172.
26. Fleisch MC, Blauer F, Gubler JG, et al. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment. Eur Respir J. 2000; 15: 205-208.
27. Hayes D Jr, Anstead MI, Kuhn RJ. Eosinophilic pneumonia induced by daptomycin. J Infect. 2007; 54: e211-e213.
28. Paralkar VR, Goradia A, Luger SM, et al. Severe eosinophilia as a manifestation of acute graft-versus-host disease. Oncology. 2008; 75: 134-136.
29. Pandit R, Scholnik A, Wulfekuhler L, et al. Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome. Am J Hematol. 2007; 82: 234-237.
30. Wilson F, Tefferi A. Acute lymphocytic leukemia with eosinophilia: two case reports and a literature review. Leuk Lymphoma. 2005; 46: 1045-1050.
31. Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore). 1998; 77: 299-312.
32. Fox B, Seed WA. Chronic eosinophilic pneumonia. Thorax. 1980; 35: 570-580.
33. Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore). 1988; 67: 154-162.
34. Naughton M, Fahy J, Fitzgerald MX. Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest. 1993; 103: 162-165.
35. Ebara H, Ikezoe J, Johkoh T, et al. Chronic eosinophilic pneumonia: evolution of chest radiograms and CT features. J Comput Assist Tomogr. 1994; 18: 737-744.
36. Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. Am J Roentgenol. 1977; 128: 1-13.
37. Dejaegher P, Demedts M. Bronchoalveolar lavage in eosinophilic pneumonia before and during corticosteroid therapy. Am Rev Respir Dis. 1984; 129: 631-632.
38. Durieu J, Wallaert B, Tonnel AB. Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia. Groupe d'Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J. 1997; 10: 286-291.
39. Philit F, Etienne-Mastroianni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med. 2002; 166: 1235-1239.
40. Pope-Harman AL, Davis WB, Christoforidis AJ, et al. Acute eosinophilic pneumonia: a summary of fifteen cases and review of the literature. Medicine (Baltimore). 1996; 75: 334-342.
41. Shintani H, Fujimura M, Ishiura Y, et al. A case of cigarette smoking-induced acute eosinophilic pneumonia showing tolerance. Chest. 2000; 117: 277-279.
42. Cheon JE, Lee KS, Jung GS, et al. Acute eosinophilic pneumonia: radiographic and CT findings in six patients. Am J Roentgenol. 1996; 167: 1195-1199.
43. King MA, Pope-Harman AL, Allen JN, et al. Acute eosinophilic pneumonia: radiologic and clinical features. Radiology. 1997; 203: 715-719.
44. Tazelaar HD, Linz LJ, Colby TV, et al. Acute eosinophilic pneumonia: histopathologic findings in nine patients. Am J Respir Crit Care Med. 1997; 155: 296-302.
45. Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984; 63: 65-81.
46. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999; 78: 26-37.
47. Solans R, Bosch JA, Perez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford). 2001; 40: 763-771.
48. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996; 75: 17-28.
49. Hasley PB, Follansbee WP, Coulehan JL. Cardiac manifestations of Churg-Strauss syndrome: report of a case and review of the literature. Am Heart J. 1990; 120: 996-999.
50. Morgan JM, Raposo L, Gibson DG. Cardiac involvement in Churg-Strauss syndrome shown by echocardiography. Br Heart J. 1989; 62: 462-466.
51. Ramakrishna G, Connolly HM, Tazelaar HD, et al. Churg-Strauss syndrome complicated by eosinophilic endomyocarditis. Mayo Clin Proc. 2000; 75: 631-635.
52. Stollberger C, Finsterer J, Winkler WB. Eosinophilic pericardial effusion in Churg-Strauss syndrome. Respir Med. 2005; 99: 377-379.
53. Val-Bernal JF, Mayorga M, Garcia-Alberdi E, et al. Churg-Strauss syndrome and sudden cardiac death. Cardiovasc Pathol. 2003; 12: 94-97.
54. Keogh KA, Specks U. Churg-Strauss syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003; 115: 284-290.
55. Davis MD, Daoud MS, McEvoy MT, et al. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol. 1997; 37: 199-203.
56. Conron M, Beynon HL. Churg-Strauss syndrome. Thorax. 2000; 55: 870-877.
57. Pagnoux C, Mahr A, Cohen P, et al. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005; 84: 115-128.
58. Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998; 53: 743-753.
59. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005; 143: 632-638.
60. Choi YH, Im JG, Han BK, et al. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest. 2000; 117: 117-124.
61. Silva CI, Muller NL, Fujimoto K, et al. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging. 2005; 20: 74-80.
62. Worthy SA, Muller NL, Hansell DM, et al. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. Am J Roentgenol. 1998; 170: 297-300.
63. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37: 187-192.
64. Schnabel A, Csernok E, Braun J, et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax. 1999; 54: 771-778.
65. Wallaert B, Gosset P, Prin L, et al. Bronchoalveolar lavage in allergic granulomatosis and angiitis. Eur Respir J. 1993; 6: 413-417.
66. Le Gall C, Pham S, Vignes S, et al. Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. Eur Respir J. 2000; 15: 978-981.
67. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975; 54: 1-27.
68. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994; 83: 2759-2779.
69. Roufosse F, Goldman M, Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med. 2006; 27: 158-170.
70. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982; 97: 78-92.
71. Flaum MA, Schooley RT, Fauci AS, et al. A clinicopathologic correlation of theidiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood. 1981; 58: 1012-1020.
72. Schooley RT, Flaum MA, Gralnick HR, et al. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood. 1981; 58: 1021-1026.
73. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348: 1201-1214.
74. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003; 101: 4660-4666.
75. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004; 18: 734-742.
76. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004; 103: 473-478.
77. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006; 117: 1292-1302.
78. Butterfield JH. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin North Am. 2007; 27: 493-518.
79. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007; 27: 333-355.
80. Cogan E, Schandene L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994; 330: 535-538.
81. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy. 2004; 59: 673-689.
82. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007; 27: 389-413.
83. Brugnoni D, Airo P, Rossi G, et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood. 1996; 87: 1416-1422.
84. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Hematol. 2000; 109: 540-548.
85. Schandene L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest. 1996; 97: 309-315.
86. Schandene L, Roufosse F, de Lavareille A, et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood. 2000; 96: 4285-4292.
87. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008; 358: 1215-1228.